» Articles » PMID: 33842343

The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Apr 12
PMID 33842343
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is an incurable neoplastic hematologic disorder characterized by malignant plasma cells, mainly in the bone marrow. MM is associated with multiple factors, such as lipid metabolism, obesity, and age-associated disease development. Although, the precise pathogenetic mechanisms remain unknown, abnormal lipid and lipoprotein levels have been reported in patients with MM. Interestingly, patients with higher APOA1 levels, the major apolipoprotein of high density lipoprotein (HDL), have better overall survival. The limited existing studies regarding serum lipoproteins in MM are inconclusive, and often contradictory. Nevertheless, it appears that deregulation of the lipoprotein transport system may facilitate the development of the disease. Here, we provide a critical review of the literature on the role of lipids and lipoproteins in MM pathophysiology. We also propose novel mechanisms, linking the development and progression of MM to the metabolism of blood lipoproteins. We anticipate that proteomic and lipidomic analyses of serum lipoproteins along with analyses of their functionality may improve our understanding and shed light on novel mechanistic aspects of MM pathophysiology.

Citing Articles

Lipids, apolipoproteins, carbohydrates, and risk of hematological malignancies.

Liu Q, Wei D, Hammar N, Yang Y, Feychting M, Zhang Z Eur J Epidemiol. 2025; .

PMID: 40038140 DOI: 10.1007/s10654-025-01207-y.


Correlation Between Bariatric Surgery and the Risk of Multiple Myeloma: Results from an Evidence-Based Strategy.

Wu Q, Zhao T, Zhu C, Da M Obes Surg. 2024; 34(4):1061-1072.

PMID: 38231452 DOI: 10.1007/s11695-024-07059-x.


Serum NMR-Based Metabolomics Profiling Identifies Lipoprotein Subfraction Variables and Amino Acid Reshuffling in Myeloma Development and Progression.

Pedersen S, Mikkelstrup M, Kristensen S, Anwardeen N, Elrayess M, Andreassen T Int J Mol Sci. 2023; 24(15).

PMID: 37569650 PMC: 10419104. DOI: 10.3390/ijms241512275.


Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures.

Dunphy K, Bazou D, Henry M, Meleady P, Miettinen J, Heckman C Cancers (Basel). 2023; 15(15).

PMID: 37568580 PMC: 10417544. DOI: 10.3390/cancers15153764.


Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis.

Bao L, Wang Y, Lu M, Chu B, Shi L, Gao S Front Endocrinol (Lausanne). 2023; 14:1157969.

PMID: 37181039 PMC: 10173308. DOI: 10.3389/fendo.2023.1157969.


References
1.
Kuliszkiewicz-Janus M, Malecki R, Mohamed A . Lipid changes occuring in the course of hematological cancers. Cell Mol Biol Lett. 2008; 13(3):465-74. PMC: 6275614. DOI: 10.2478/s11658-008-0014-9. View

2.
Kyrgiou M, Kalliala I, Markozannes G, Gunter M, Paraskevaidis E, Gabra H . Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017; 356:j477. PMC: 5421437. DOI: 10.1136/bmj.j477. View

3.
Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki J . Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014; 124(25):3748-57. PMC: 4263983. DOI: 10.1182/blood-2014-05-576116. View

4.
Bergsagel P, Kuehl W . Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005; 23(26):6333-8. DOI: 10.1200/JCO.2005.05.021. View

5.
Laroche C, Beney L, Marechal P, Gervais P . The effect of osmotic pressure on the membrane fluidity of Saccharomyces cerevisiae at different physiological temperatures. Appl Microbiol Biotechnol. 2001; 56(1-2):249-54. DOI: 10.1007/s002530000583. View